Savara Launches Public Offering to Fund MOLBREEVI Therapy
Savara, the pharmaceutical company behind MOLBREEVI therapy, has initiated an underwritten public offering of its common stock and pre-funded warrants. Led by CEO Roger L. Mills, the company aims to raise funds for clinical development and regulatory approval of its flagship product.
The offering, which began recently, involves shares of common stock and pre-funded warrants. Savara has given underwriters a 30-day option to buy an additional 15% of these shares and warrants. Proceeds from the offering will be allocated towards funding clinical development of MOLBREEVI, seeking regulatory approval, and general corporate purposes. This move signals Savara's commitment to advancing MOLBREEVI therapy and strengthening its financial position.
Savara's public offering is underway, with the potential to raise significant funds for the company's growth. The offering, led by CEO Roger L. Mills, is a strategic step towards pushing MOLBREEVI therapy through clinical trials and regulatory approval processes.
